| Literature DB >> 29157261 |
Abstract
Nanotechnology is regarded as a key technology of the twenty-first century. Despite the many advantages of nanotechnology it is also known that engineered nanoparticles (NPs) may cause adverse health effects in humans. Reports on toxic effects of NPs relay mainly on conventional (phenotypic) testing but studies of changes in epigenome, transcriptome, proteome, and metabolome induced by NPs have also been performed. NPs most relevant for human exposure in consumer, health and food products are metal, metal oxide and carbon-based NPs. They were also studied quite frequently with omics technologies and an overview of the study results can serve to answer the question if screening for established targets of nanotoxicity (e.g. cell death, proliferation, oxidative stress, and inflammation) is sufficient or if omics techniques are needed to reveal new targets. Regulated pathways identified by omics techniques were confirmed by phenotypic assays performed in the same study and comparison of particle types and cells by the same group indicated a more cell/organ-specific than particle specific regulation pattern. Between different studies moderate overlap of the regulated pathways was observed and cell-specific regulation is less obvious. The lack of standardization in particle exposure, in omics technologies, difficulties to translate mechanistic data to phenotypes and comparison with human in vivo data currently limit the use of these technologies in the prediction of toxic effects by NPs.Entities:
Keywords: Cytotoxicity; Nanoparticles; Omics technologies; Proteomics; Transcriptomics
Mesh:
Substances:
Year: 2017 PMID: 29157261 PMCID: PMC5697164 DOI: 10.1186/s12951-017-0320-3
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Models, readout parameters and methods in systems toxicology. a Analytical techniques to characterize NP—macromolecule interactions include spectroscopical techniques, such as UV–vis spectroscopy, photoluminescence, infrared absorption, Raman scattering, circular dichroism spectroscopy, electron paramagnetic spectroscopy, and fluorescence spectroscopy. b Biological assays exploit these technologies and, in addition to that, rely on absorbance, fluorescence and luminescence readers, image analysis and a variety of separation and detection platforms (high-pressure liquid chromatography, gas chromatography, mass spectrometry, nuclear magnetic resonance spectroscopy, electrophoresis, etc.). c Further technologies are used for the analysis of organs, mainly histopathology and various staining techniques. Effects on the entire organism can also be detected by imaging techniques (magnetic resonance imaging, ultrasound, computed tomography, radiography, photoacoustic tomography, positron emission tomography, single photon emission computed tomography, thermography) as well as by observation of changes in behavior, appearance, deterioration of health, and death. The predictive value of the obtained results for human toxicology increases from top to bottom
Characterization of cell toxicity according to changes in mRNA expression (transcriptomics), proteome (proteomics), and metabolome (metabolomics) with categories
| Particle | Size (nm) | Cell | Exp | Regulated pathway(s) | St | Im | De | Pr | Mo | Me | Ve | Si | O | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A. Transcriptomics | ||||||||||||||
| Ag | 5 | L51784 | 3–6 µg/ml; 4 h | Ox. stress, DNA repair | X | X | [ | |||||||
| Ag | 5, 100 | U937 | 1–25 µg/ml; 24 h | 5 nm: ox. stress, inflammation | X | X | [ | |||||||
| Ag | 20 | Human dermal fetal fibroblasts | 3–6 µg/ml; 4 h | Cytoskeleton, energy metabolism, DNA damage | X | X | X | [ | ||||||
| Ag | 20, 30, 60 | Caco-2, MCF-7 | 5–25 µg/ml; 6–24 h | Proliferation, stress response, ox. stress | X | X | [ | |||||||
| Ag | 20, 50 | HepG2 | 2.5 µg/ml; 4–24 h | 20 nm: stress response | X | [ | ||||||||
| Ag | 20, 50 | Human dermal fibroblasts | 200 µM; 1–8 h | Cytoskeleton, insulin, HGF signaling, MAPK signaling, ATP content, apoptosis, cytoskeleton | X | X | X | X | X | [ | ||||
| Ag | 20, 50 | A549 | 1–3 µg/ml; 24–48 h | Cell cycle, ox. stress | X | X | [ | |||||||
| Ag | 20, 50 | HepG2 | 1–3 µg/ml; 24–48 h | Cell cycle progression (low dose), morphological damage (high dose) | X | [ | ||||||||
| Ag | < 100 | HeLa | 20 µg/ml; 24–48 h | Metabolic process, cellular process, stress response, apoptosis, cell cycle | X | X | X | X | [ | |||||
| Ag | 100 | Embryonic rat cells | 20 µg/ml; 48 h | Energy, metabolism, O2 transport, inflammation, molecular binding | X | X | X | [ | ||||||
| Al2O3 | < 100 | A549 | 100 µg/ml; 0–72 h | Cell death, cell cycle arrest | X | X | [ | |||||||
| Au (NH2, COOH, OH) | 17–22 | Human mesenchymal stem cells | 50 µg/ml; 4 h | TFG-β, FGF-2 | X | [ | ||||||||
| Au | 5, 30 | Caco-2 | 200–300 µM; 24–72 h | Ox. stress, apoptosis, growth inhibition | X | X | X | [ | ||||||
| Au | 20, 34, 61, 113 | Caco-2/M-cells | 0.5–64 µg/ml; 10–21 days | Ox. stress, ER stress, apoptosis | X | X | [ | |||||||
Exposure (Exp) with concentration and collection time after treatment with nanoparticles is given. If a range is indicated, several concentrations or time points have been evaluated
Characterization of in vivo toxicity according to changes in mRNA expression (transcriptomics), proteome (proteomics), and metabolome (metabolomics) with categories
| P | Size | Sp | Appl | Exp | Regulated pathway(s) | St | Im | De | Pr | Mo | Me | Ve | Si | O | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A. Transcriptomics | |||||||||||||||
| Ag | 20 | Rat | Inhal | 381 µg/m3; 12 weeks | Kidney: cell cycle, xenobiotic metabolism, extracellular signaling | X | X | [ | |||||||
| Au | 4, 100 | Mouse | Iv | 426 mg/kg; 30 min | Liver: apoptosis, cell cycle, inflammation, metabolic process | X | X | X | X | [ | |||||
| CNT | 4 × 67, 0.8 × 11, 3.8 × 49, 5.7 × 49 | Mouse | It, oroph, inhal, | Meta-analysis | Lung: inflammation resembling different disease pattern | X | [ | ||||||||
| Cu | 25 | Rat | Oral | 50–200 µg/kg; 5 days | Kidney: coagulation, cell signaling, amino acid metabolism | X | X | [ | |||||||
| C60, NiO | 60, 59 | Rat | Inhal | 0.12 mg/m3; 3 days–4 weeks | Lung: C60: immune process; NiO: ox. stress, inflammation | X | X | [ | |||||||
| SiO2 (Cd-doped) | 20 | Rat | It | 1 mg/animal; 7–30 days | Lung: circadian rhythm, inflammation, cell cycle | X | X | X | [ | ||||||
| TiO2 | 5–6 | Mouse | Ig | 10 mg/kg; 90 days | Ovary: estradiol, progesterone metabolism | X | [ | ||||||||
| TiO2 | 5–6 | Mouse | Ig | 10 mg/kg; 90 days | Liver: inflammation, apoptosis, ox. stress, metabolic process, cell cycle, signal transduction, cytoskeleton, cell differentiation | X | X | X | X | X | X | X | [ | ||
| TiO2 | 5–6 | Mouse | Oral | 2.5–10 µg/kg; 90 days | Spleen: inflammation, apoptosis, ox. stress, metabolic processes, ion transport, signal transduction, cell proliferation/division, cytoskeleton | X | X | X | X | X | X | [ | |||
| TiO2 | 8, 20, 300 | Mouse | It | 18–486 µg/animal; 1–90 days | Lung: inflammation, all same pattern | X | [ | ||||||||
| TiO2 | 10, 20.6, 38 | Mouse | It | 18–486 µg/animal; 1–28 days | Lung: inflammation | X | [ | ||||||||
| TiO2 | 10.5, 10, 20.6 | Mouse | It, oroph, inhal, | Meta-analysis | Lung: inflammation resembling different disease pattern | X | [ | ||||||||
| TiO2 | 20.6 | Mouse | Inhal | 42 mg/m3; 1–22 days pn | Liver of offspring: females retinoid pathway | X | [ | ||||||||
| TiO2 | 20.6 | Mouse | It | 162 µg/animal; 1–22 days | Lung: inflammation | X | [ | ||||||||
| B. Proteomics | |||||||||||||||
| TiO2 | < 25 | Mouse | Ip | 100 µg/animal; 7 days | Lung: ox. stress | X | [ | ||||||||
| TiO2 | < 25 | Mouse | Ip | 100 µg/animal; 7 days | Liver: inflammation, apoptosis, ox. stress | X | X | X | [ | ||||||
| TiO2 | < 25 | Mouse | Ip | 100 µg/animal; 7 days | Brain: ox. stress | X | [ | ||||||||
| TiO2 | < 25 | Mouse | Ip | 100 µg/animal; 7 days | Kidney: ox. stress, signal transduction | X | X | [ | |||||||
| TiO2 | 25 | Mouse | Id | 5 µg/animal; 24 h | Lymph node: inflammation, lipid metabolism, mRNA processing, nucleosome assembly | X | X | [ | |||||||
| ZnO | 35 | Rat | Inhal | 12.1 mg/m3; 24 h | Lung: S100A8, S100A9, inflammation | X | [ | ||||||||
| C. Metabolomics | |||||||||||||||
| MnO | 10 | Rat | Iv | 10 mg/kg; 6–48 h | Plasma, urine, tissues: lipid, energy metabolism, amino acid metabolism | X | [ | ||||||||
| PS, lipid polymeric | 50, 40, 143, 160, 165 | Mouse | It | 200, 500 µg/animal; 24 h | BAL: inflammation (all, hydrophobic > less hydrophobic) | X | [ | ||||||||
| ZnO | 35, 250 | Rat | Inhal | 1–5 mg/kg; 24 h | BAL, lung: cell anti-oxidation, energy metabolism, DNA damage and membrane stability | X | X | X | [ | ||||||
Application (Appl) and Exposure (Exp) with dose and duration of treatment with nanoparticles is given. If a range is indicated, several concentrations or time points have been evaluated
Limitations that hinder the broad use of omics technologies in nanotoxicology
| Independent from the technology | Technology linked |
|---|---|
| Lack of standardization of particle exposure | Request for high sample quality (freezing, protection against degradation) |
| Sample pre-treatment | Expertise in bioinformatics needed for data analysis |
| Cell type used for testing | Lack of standardization of sample preparation |
| Medium composition | Predictive value of the omics techniques not entirely clear |
| Relevant concentration range |